Clinical Trial Update: Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for Genexine's genetically modified mesenchymal stem cell therapy targeting head and neck cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Genetically Modified Mesenchymal Stem Cell Therapy (Head and Neck Cancer)

Snippet

Sponsor: Genexine, Inc. | Conditions: Head and Neck Cancer | Phase 1 | Status: COMPLETED